ITMR - Itamar Medical Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.50
-0.18 (-1.86%)
As of 9:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close9.68
Open9.68
Bid9.40 x 900
Ask9.98 x 1000
Day's Range9.50 - 9.50
52 Week Range8.27 - 14.00
Volume20
Avg. Volume1,104
Market Cap94.908M
Beta (3Y Monthly)0.28
PE Ratio (TTM)N/A
EPS (TTM)-0.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.43
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    Itamar Medical Reports Record Second Quarter 2019 Revenues

    - Total Second Quarter Revenues Increase 21% to $7.4 Million -  - WatchPATTM Revenues Increase 16% in the Second Quarter to $6.5 Million -  - Company to Host Conference Call.

  • GlobeNewswire21 days ago

    Itamar Medical to Report Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 14, 2019

    Itamar Medical Ltd. (ITMR) (ITMR.TA), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, announced today that it will report its unaudited financial results for the second quarter of 2019 before the U.S. market opens on Wednesday, August 14, 2019. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update. The call will be hosted by Gilad Glick, President and CEO, and Shy Basson, CFO.

  • PR Newswire2 months ago

    Frost & Sullivan Begins Coverage of Itamar Medical

    TEL AVIV, Israel , June 26, 2019 /PRNewswire/ -- Itamar Medical's (NASDAQ: ITMR) (TASE: ITMR)  revolutionary technology enables cardiologists to make better decisions and results in 30% assumed revenue ...

  • GlobeNewswire2 months ago

    Itamar Medical’s WatchPAT™ One, the First and Only Fully Disposable Home Sleep Apnea Test Receives FDA 510(k) Clearance

    Itamar Medical Ltd. (ITMR) (ITMR.TA), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for WatchPAT One, the latest innovation of its WatchPAT technology and the first and only fully disposable Home Sleep Apnea Test (HSAT). WatchPAT One incorporates the technology and comfort advances of WatchPAT 300, which received 510(k) clearance in August 2018 and was launched in March 2019.

  • GlobeNewswire3 months ago

    Itamar Medical and BioTel Heart, a Division of BioTelemetry, Expand Collaboration to Offer Itamar’s Total Sleep Solution™ to BioTel Heart Cardiology Customers

    Itamar Medical Ltd. (NASDAQ and TASE:ITMR), a company that develops, manufacturers and markets non-invasive diagnostic devices for sleep apnea with a focus on the cardiology market, and BioTel Heart, a division of BioTelemetry, Inc. (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced an expanded collaboration to make Itamar Medical’s Total Sleep Solution available to select BioTel Heart cardiology customers in the United States. The collaboration is designed to respond to the growing demand for home sleep apnea testing among cardiologists, who recognize effective sleep apnea management as a critical strategy for improving health in patients with cardiac disease.

  • GlobeNewswire3 months ago

    Itamar Medical Reports First Quarter 2019 Financial Results

    - WatchPAT™ Revenues Increase 15% to $5.8 Million -  - U.S. WatchPAT Revenues Increase 34% to $4.3 Million - - Total Revenues Increase 11% to $6.1 Million - CAESAREA, Israel,.

  • GlobeNewswire5 months ago

    Itamar Medical Advances Simple, Accurate and Reliable Home Sleep Apnea Testing with Launch of WatchPAT™ 300

    Itamar Medical Ltd. (Nasdaq & TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today announced the launch of WatchPAT 300, the next generation WatchPAT system for home sleep apnea testing. WatchPAT 300 includes several advances that are designed to enhance both patients’ WatchPAT experience as well as provide physicians with a trusted and cost-effective method for rapid, scalable and effective diagnosis of sleep apnea. “Sleep apnea has reached epidemic levels and is estimated to affect 25 percent of adults worldwide,” said Gilad Glick, President and CEO of Itamar Medical.

  • GlobeNewswire5 months ago

    Itamar Medical Reports Fourth Quarter and Full Year 2018 Financial Results With Record Revenues

    Full Year 2018 Revenues Increased 17% to $24.2 Million; WatchPAT™ Revenues Increased 24% to $22.4 Million Fourth Quarter 2018 Revenues Increased 9% to $6.6 Million; WatchPAT.

  • GlobeNewswire5 months ago

    Itamar Medical to Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019

    CAESAREA, Israel, March 12, 2019 -- Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical device company that develops, manufactures and markets non-invasive diagnostic.